Reframe Daily: More corneas now usable, lung cancer combo extends life, HIV vaccine step forward

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A randomized trial showed surgeons can safely use more donor corneas for transplants; pairing the pill osimertinib with chemotherapy helped people with EGFR lung cancer live longer; adding durvalumab to BCG kept high-risk bladder cancer from coming back longer; a noninvasive brain-stimulation therapy with rehab reduced disability after stroke; and a new vaccine approach sparked several kinds of powerful HIV-blocking antibodies in early tests.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: Surgeons can safely use more donor corneas. That means more people can get sight-restoring surgery sooner.

Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (already used corneal-transplant surgery; this RCT supports expanding the donor pool now without new approvals). 

Good news: A common lung-cancer pill plus chemo helped people live longer. More patients could benefit from a treatment they can already get.

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Market readiness: 🙂🙂🙂🙂 (phase 3 RCT using already-approved drugs; practice change likely while label/guidelines catch up). 

Good news: For high-risk bladder cancer that hasn’t invaded muscle, adding immunotherapy to BCG kept cancer away longer.

Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer: a randomized phase 3 trial

Market readiness: 🙂🙂🙂🙂 (phase 3, drugs already marketed; could be adopted soon pending guideline/label updates). 

Good news: A gentle, noninvasive brain-stimulation approach plus rehab reduced disability after stroke in a randomized trial.

Electromagnetic Stimulation to Reduce Disability After Ischemic Stroke: The EMAGINE Randomized Clinical Trial

Market readiness: 🙂🙂🙂 (promising RCT, but device/therapy protocol still needs regulatory and clinical adoption steps). 

Good news: A vaccine strategy taught the immune system to make several types of strong HIV-blocking antibodies at once—an early step toward a better HIV vaccine.

Simultaneous induction of multiple classes of broadly neutralizing antibodies

Market readiness: 🙂 (preclinical/early-stage immunology work; years from consumer use).

Thank you for taking the time to take care of yourself and your loved ones.